Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Woodcock Hopes I-SPY 2 Trial Is 'Blazing The Trail' For Future Adaptive Design Uptake

Executive Summary

CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them. 
Advertisement

Related Content

MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations
Latin America Notebook: Advancing Adaptive Trial Designs, Translating ICH Guidelines, Sharing Confidential Information
Platform Trials Could Be A Solution To Expanded Access, Woodcock Says
NASH Drug Development Guidance Encourages Sponsors To Adopt Innovative Trial Designs
Adaptive Clinical Trial Designs: US FDA Provides Checklist To Begin Study
“One Continuous Trial” In Oncology: US FDA Offers Guidance And Encouragement
US FDA's Gottlieb Touts 'Seamless' Clinical Trials, Worries About Second-To-Market Products
Orphan Drug Development: Could We Be Seeing The End Of P Values?
Master Protocols In Practice

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS123861

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel